Accounts for up to 30% of reported 'non-responder' cases in peptide research protocols
doi: 10.3389/fphar.2025.1602976 Received 30 March 2025 Revised 13 November 2025 Accepted 14 November 2025 Published 19 December 2025 Volume 16 - 2025 Edited by Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa Reviewed by Kacper Nijakowski, Poznan University of Medical Sciences, Poland Miriam Njoki Karinja, Science for Africa Foundation, Kenya Updates Copyright 2025 Mazur, Ndokaj, Salerno, Vallone, Ardan, Bietolini, Carrouel, Wilk, Sarig, Ottolenghi and Bourgeois
It can also be developed in a laboratory by extracting it from microorganisms
Clinical trials evaluated AOD-9604 for durations ranging from single doses to 24 weeks of continuous daily administration
Learn precisely whats a B12 shot as we unravel the mysteries behind this popular health phenomenon